VERA - Vera Therapeutics soars 16% on three new favorable view from analysts

Evercore ISI analyst Liisa Bayko initiates coverage on Vera Therapeutics ([[VERA]] +15.5%) with an Outperform rating, and price target ((PT)) set to $24.Vera was also rated new buy at Jefferies, analyst Maury Raycroft set PT to $27.In addition, Vera was initiated with an Outperform rating at Cowen.Vera is focused on developing treatments for patients with immunoglobulin A nephropathy (IgAN) and Lupus Nephritis, two kidney diseases.The Company's lead product candidate atacicept is in-licensed from Merck KGaA in October 2020.Vera plans to initiate patient screening for its Phase 2b trial in IgAN in Q2 2021, and expects topline results in Q4 2022.See VERA's total return performance since its IPO last month vs. competitors (past one month).The company recently made a U.S. debut in May. VERA is trading ~41% higher at around $15.55, above IPO price of $11.

For further details see:

Vera Therapeutics soars 16% on three new favorable view from analysts